243 related articles for article (PubMed ID: 24347760)
1. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
Grover ND; Limaye RP; Gokhale DV; Patil TR
Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
[TBL] [Abstract][Full Text] [Related]
2. Zonisamide in Parkinson's disease: a current update.
Goel A; Sugumaran R; Narayan SK
Neurol Sci; 2021 Oct; 42(10):4123-4129. PubMed ID: 34448999
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
Murata M
Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
Matsunaga S; Kishi T; Iwata N
J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
[TBL] [Abstract][Full Text] [Related]
5. Zonisamide: a new drug for Parkinson's disease.
Murata M
Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Aboulatta L; Haidar L; Abou-Setta A; Askin N; Rabbani R; Lavu A; Peymani P; Zarychanski R; Eltonsy S
CNS Drugs; 2023 Nov; 37(11):941-956. PubMed ID: 37973769
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of Parkinson's disease--up to date].
Murata M
Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
[TBL] [Abstract][Full Text] [Related]
9. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide: in Parkinson's disease.
Yang LP; Perry CM
CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
[TBL] [Abstract][Full Text] [Related]
11. Zonisamide has beneficial effects on Parkinson's disease patients.
Murata M; Horiuchi E; Kanazawa I
Neurosci Res; 2001 Dec; 41(4):397-9. PubMed ID: 11755227
[TBL] [Abstract][Full Text] [Related]
12. Zonisamide for the Treatment of Parkinson Disease: A Current Update.
Li C; Xue L; Liu Y; Yang Z; Chi S; Xie A
Front Neurosci; 2020; 14():574652. PubMed ID: 33408605
[TBL] [Abstract][Full Text] [Related]
13. Comparison of zonisamide with non-levodopa, anti-Parkinson's disease drugs in the incidence of Parkinson's disease-relevant symptoms.
Iwaki H; Tagawa M; Iwasaki K; Kawakami K; Nomoto M
J Neurol Sci; 2019 Jul; 402():145-152. PubMed ID: 31151065
[TBL] [Abstract][Full Text] [Related]
14. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y
J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
16. Non-dopaminergic treatments for motor control in Parkinson's disease.
Fox SH
Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
18. The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study.
Kon T; Ueno T; Haga R; Tomiyama M
Brain Behav; 2018 Aug; 8(8):e01036. PubMed ID: 29956879
[TBL] [Abstract][Full Text] [Related]
19. Zonisamide in managing impulse control disorders in Parkinson's disease.
Bermejo PE; Ruiz-Huete C; Anciones B
J Neurol; 2010 Oct; 257(10):1682-5. PubMed ID: 20509031
[TBL] [Abstract][Full Text] [Related]
20. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease.
Ueno SI; Saiki S; Fujimaki M; Takeshige-Amano H; Hatano T; Oyama G; Ishikawa KI; Yamaguchi A; Nojiri S; Akamatsu W; Hattori N
Cells; 2018 Dec; 8(1):. PubMed ID: 30597973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
